Comparing Local and Systemic Control between Partial- and Whole-Breast Radiotherapy in Low-Risk Breast Cancer-A Meta-Analysis of Randomized Trials.

breast cancer local recurrence partial-breast treatment radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 Jun 2021
Historique:
received: 14 05 2021
revised: 09 06 2021
accepted: 09 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

The standard treatment for localized low-risk breast cancer is breast-conserving surgery, followed by adjuvant radiotherapy and appropriate systemic therapy. As the majority of local recurrences occur at the site of the primary tumor, numerous trials have investigated partial-breast irradiation (PBI) instead of whole-breast treatment (WBI) using a multitude of irradiation techniques and fractionation regimens. This meta-analysis addresses the impact on disease-specific endpoints, such as local and regional control, as well as disease-free survival of PBI compared to that of WBI in published randomized trials. We conducted a systematic literature review and searched for randomized trials comparing WBI and PBI in early-stage breast cancer with publication dates after 2009. The meta-analysis was based on the published event rates and the effect sizes for available oncological endpoints of at least two trials reporting on them. We evaluated in-breast tumor recurrences (IBTR), local recurrences at the primary site and elsewhere in the ipsilateral breast, regional recurrences (RR), distant metastasis-free interval (DMFI), disease-free survival (DFS), contralateral breast cancer (CBC), and second primary cancer (SPC). Furthermore, we aimed to assess the impact of different PBI techniques and subgroups on IBTR. We performed all statistical analyses using the inverse variance heterogeneity model to pool effect sizes. For the intended meta-analysis, we identified 13 trials (overall 15,561 patients) randomizing between PBI and WBI. IBTR was significantly higher after PBI (OR = 1.66; CI-95%: 1.07-2.58; Limiting the target volume to partial-breast radiotherapy appears to be appropriate when selecting patients with a low risk for local and regional recurrences and using a suitable technique.

Identifiants

pubmed: 34199281
pii: cancers13122967
doi: 10.3390/cancers13122967
pmc: PMC8231985
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Breast Cancer Res Treat. 2013 Aug;140(3):519-25
pubmed: 23877341
Lancet. 2019 Dec 14;394(10215):2165-2172
pubmed: 31813635
BMC Med Res Methodol. 2007 Jan 23;7:5
pubmed: 17244367
J Natl Cancer Inst. 1996 Nov 20;88(22):1659-64
pubmed: 8931610
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Lancet Oncol. 2018 Jun;19(6):834-844
pubmed: 29695348
J Natl Cancer Inst. 2019 Jul 1;111(7):641-643
pubmed: 30698728
Cancer. 1986 May 1;57(9):1717-24
pubmed: 2856856
Lancet Oncol. 2021 May;22(5):597-608
pubmed: 33845035
Transl Oncol. 2013 Dec 01;6(6):619-27
pubmed: 24466364
Br J Radiol. 2018 May;91(1085):20170565
pubmed: 29513031
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
J Natl Cancer Inst. 2000 Jul 19;92(14):1143-50
pubmed: 10904087
Clin Transl Oncol. 2021 Apr 20;:
pubmed: 33880724
Brachytherapy. 2020 Jul - Aug;19(4):491-498
pubmed: 32340902
Lancet. 2016 Jan 16;387(10015):229-38
pubmed: 26494415
Lancet Oncol. 2017 Feb;18(2):259-268
pubmed: 28094198
Clin Breast Cancer. 2012 Aug;12(4):259-63
pubmed: 22658839
Radiat Oncol. 2017 Mar 23;12(1):60
pubmed: 28335784
Eur J Cancer. 2015 Mar;51(4):451-463
pubmed: 25605582
Am J Clin Pathol. 2003 Oct;120(4):500-27
pubmed: 14560562
Radiother Oncol. 2013 Aug;108(2):197-202
pubmed: 23742961
Med Phys. 2018 Jun 23;:
pubmed: 29935088
Radiat Oncol. 2013 Jan 07;8:9
pubmed: 23294485
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
Acta Oncol. 2008;47(4):672-81
pubmed: 18465335
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):724-31
pubmed: 17524571
Lancet Oncol. 2015 Mar;16(3):266-73
pubmed: 25637340
J Clin Oncol. 2014 Nov 10;32(32):3600-6
pubmed: 25135994
Am J Clin Oncol. 1987 Dec;10(6):461-8
pubmed: 3687830
Eur J Cancer. 2010 Jan;46(1):95-101
pubmed: 19879131
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Ann Surg Oncol. 2013 Oct;20(10):3279-85
pubmed: 23975302
Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):998-1006
pubmed: 33186620
Clin Breast Cancer. 2021 Jun;21(3):231-238
pubmed: 33121891
Lancet. 2019 Dec 14;394(10215):2155-2164
pubmed: 31813636
N Engl J Med. 2004 Sep 2;351(10):963-70
pubmed: 15342804
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):55-64
pubmed: 27511847
J Clin Oncol. 2017 May 20;35(15):1641-1649
pubmed: 28319436
Breast Cancer Res Treat. 2019 Jun;175(3):531-545
pubmed: 30929116
Health Technol Assess. 2011 Mar;15(12):i-xi, 1-57
pubmed: 21366974
Ann Surg Oncol. 2021 Jan 3;:
pubmed: 33393051
Contemp Clin Trials. 2015 Nov;45(Pt A):130-8
pubmed: 26003435
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):968-76
pubmed: 25832689
J Clin Oncol. 2019 Feb 1;37(4):305-317
pubmed: 30532984
Eur J Cancer. 2016 Nov;67:57-65
pubmed: 27614164
J Clin Oncol. 2013 Nov 10;31(32):4038-45
pubmed: 23835717
Eur J Cancer. 2017 May;76:17-26
pubmed: 28262584
Cochrane Database Syst Rev. 2016 Jul 18;7:CD007077
pubmed: 27425375
Radiother Oncol. 2018 Sep;128(3):411-420
pubmed: 29691075
J Clin Oncol. 1997 Mar;15(3):963-8
pubmed: 9060534
Cancers (Basel). 2020 Aug 17;12(8):
pubmed: 32824414
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1173-81
pubmed: 15519789
J Clin Oncol. 2013 Jul 1;31(19):2382-7
pubmed: 23690420
Cancer. 1995 Jul 1;76(1):32-45
pubmed: 8630874
JAMA Oncol. 2020 Jul 1;6(7):e200249
pubmed: 32239210
J Clin Oncol. 2020 Dec 10;38(35):4175-4183
pubmed: 32840419
J Clin Oncol. 1992 Jun;10(6):976-83
pubmed: 1588378
Radiother Oncol. 2019 Jul;136:190-196
pubmed: 31015124
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1127-33
pubmed: 22981707
Cancer. 1985 Sep 1;56(5):979-90
pubmed: 2990668
Radiother Oncol. 2017 Apr;123(1):1-9
pubmed: 28391871
Radiother Oncol. 2019 May;134:220-230
pubmed: 31005219
J Clin Oncol. 2002 Oct 15;20(20):4141-9
pubmed: 12377957
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):509-15
pubmed: 19700248
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e159-64
pubmed: 22579378
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):683-693
pubmed: 32437921
Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):575-83
pubmed: 8226151
Lancet Oncol. 2013 Dec;14(13):1269-77
pubmed: 24225155
Breast J. 2014 Mar-Apr;20(2):116-24
pubmed: 24372818
Breast. 2012 Feb;21(1):46-9
pubmed: 21865044
Virchows Arch A Pathol Anat Histopathol. 1992;421(2):115-9
pubmed: 1325088
Lancet. 2010 Jul 10;376(9735):91-102
pubmed: 20570343
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
Radiother Oncol. 1996 Jun;39(3):223-7
pubmed: 8783398
Ann Oncol. 2001 Jul;12(7):997-1003
pubmed: 11521809
Breast J. 2010 May-Jun;16(3):245-51
pubmed: 20210799
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):694-702
pubmed: 17531400
Eur J Cancer. 2003 Aug;39(12):1690-7
pubmed: 12888363
Breast Cancer Res Treat. 2012 Aug;135(1):253-60
pubmed: 22842984
Strahlenther Onkol. 2010 Feb;186(2):113-114
pubmed: 20127229
N Engl J Med. 2004 Sep 2;351(10):971-7
pubmed: 15342805
J Clin Oncol. 1999 Aug;17(8):2326-33
pubmed: 10561294
Breast Cancer Res Treat. 2000 Aug;62(3):177-84
pubmed: 11072782
Clin Oncol (R Coll Radiol). 1993;5(5):278-83
pubmed: 8305334
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):19-25
pubmed: 20471183
Lancet. 2017 Sep 9;390(10099):1048-1060
pubmed: 28779963
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604
Eur J Cancer. 2013 Jul;49(10):2294-302
pubmed: 23523089
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):259-265
pubmed: 27478165
Radiother Oncol. 2009 Apr;91(1):16-22
pubmed: 19178972
Ann Surg Oncol. 2013 Apr;20(4):1275-81
pubmed: 23054123
Radiother Oncol. 2015 Jan;114(1):42-9
pubmed: 25480094
Health Technol Assess. 2016 Sep;20(73):1-188
pubmed: 27689969
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79
pubmed: 27866865
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1051-7
pubmed: 24161420
Brachytherapy. 2018 Jan - Feb;17(1):154-170
pubmed: 29074088
Radiat Oncol. 2018 Apr 13;13(1):68
pubmed: 29653541
J Natl Cancer Inst. 1990 Feb 21;82(4):277-82
pubmed: 2405171
BMJ. 2020 Aug 19;370:m2836
pubmed: 32816842
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Lancet Oncol. 2015 Jan;16(1):47-56
pubmed: 25500422

Auteurs

Jan Haussmann (J)

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany.

Wilfried Budach (W)

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany.

Vratislav Strnad (V)

Department of Radiation Oncology, University Erlangen, 91054 Erlangen, Germany.

Stefanie Corradini (S)

Department of Radiation Oncology, University Hospital LMU (Ludwig Maximillian), 81377 Munich, Germany.

David Krug (D)

Department of Radiation Oncology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany.

Livia Schmidt (L)

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany.

Balint Tamaskovics (B)

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany.

Edwin Bölke (E)

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany.

Ioannis Simiantonakis (I)

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany.

Kai Kammers (K)

Division of Biostatistics and Bioinformatics, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Christiane Matuschek (C)

Department of Radiation Oncology, Heinrich Heine University, 40225 Dusseldorf, Germany.

Classifications MeSH